Effect of Tiotropium and Olodaterol on Symptoms and Patient-reported Outcomes in Patients with COPD: Results from Four Randomised, Double-blind Studies

Overview

Journal NPJ Prim Care Respir Med

Specialties Public Health
Pulmonary Medicine

Date 2017 Feb 4

PMID 28154373

Citations 15

Authors

Gary T Ferguson

Jill Karpel

Nathan Bennett

Emmanuelle Clerisme-Beaty

Lars Gronke

Florian Voss

Roland Buhl

Affiliations

Soon will be listed here.

Abstract

Chronic Obstructive Pulmonary Disease: COMBINED INHALER PROVES EFFECTIVE: Results from four in-depth studies show that a combined inhaler is very effective for treatment of moderate to severe chronic lung disease. Alleviating the symptoms of chronic obstructive pulmonary disease (COPD), particularly sleep disturbance, is crucial to enhancing patients' quality of life. Gary Ferguson at the Pulmonary Research Institute of Southeast Michigan, together with other scientists across the USA and Germany, analysed data from four large-scale studies to evaluate the efficacy of STIOLTO Respimat, a combination of two bronchodilators-tiotropium, and olodaterol, which tackle airway obstruction and breathlessness, improving long-term lung function. They found that the new drug combination triggered significant improvements in patients' quality of life and levels of breathlessness. Use of night-time rescue medication in patients on STIOLTO Respimat was considerably reduced. A greater number of patients responded positively to the combined inhaler than to monotherapy.

Citing Articles

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD.

Huang W, Chen C, Liao W, Wu B, Chen W, Tu C J Clin Med. 2022; 11(23).

PMID: 36498738 PMC: 9739795. DOI: 10.3390/jcm11237165.

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations.

Miravitlles M, Kawayama T, Dreher M J Clin Med. 2022; 11(22).

PMID: 36431099 PMC: 9692772. DOI: 10.3390/jcm11226623.

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow.

Mahler D, Ludwig-Sengpiel A, Ferguson G, de la Hoz A, Ritz J, Shaikh A Int J Chron Obstruct Pulmon Dis. 2021; 16:2455-2465.

PMID: 34511891 PMC: 8414074. DOI: 10.2147/COPD.S324467.

Future concepts in bronchodilation for COPD: dual- monotherapy.

Singh D, Donohue J, Boucot I, Barnes N, Compton C, Martinez F Eur Respir Rev. 2021; 30(160).

PMID: 34415847 PMC: 9489138. DOI: 10.1183/16000617.0023-2021.

An Observational Study Assessing Changes in Health and Functional Status in Patients with Chronic Obstructive Pulmonary Disease (COPD) During Therapy with Spiolto Respimat in Everyday Clinical Practice: The Greek ELLACTO Study.

Kosmas E, Titopoulos I, Patentalakis G, Nikas N Pulm Ther. 2021; 7(2):429-443.

PMID: 33939158 PMC: 8589918. DOI: 10.1007/s41030-021-00156-7.

References

Agusti A, Hedner J, Marin J, Barbe F, Cazzola M, Rennard S . Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011; 20(121):183-94. PMC: 9584119. DOI: 10.1183/09059180.00004311. View

Beeh K, Derom E, Echave-Sustaeta J, Gronke L, Hamilton A, Zhai D . The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study). Int J Chron Obstruct Pulmon Dis. 2016; 11:193-205. PMC: 4745834. DOI: 10.2147/COPD.S95055. View

Wacker M, Hunger M, Karrasch S, Heinrich J, Peters A, Schulz H . Health-related quality of life and chronic obstructive pulmonary disease in early stages - longitudinal results from the population-based KORA cohort in a working age population. BMC Pulm Med. 2014; 14:134. PMC: 4130122. DOI: 10.1186/1471-2466-14-134. View

Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba F, Richter K . Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005; 128(3):1168-78. DOI: 10.1378/chest.128.3.1168. View

Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S . Comorbidities of COPD. Eur Respir Rev. 2013; 22(130):454-75. PMC: 9639181. DOI: 10.1183/09059180.00008612. View

Beeh K, Westerman J, Kirsten A, Hebert J, Gronke L, Hamilton A . The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015; 32:53-9. DOI: 10.1016/j.pupt.2015.04.002. View

Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo M . Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014; 9:697-714. PMC: 4094569. DOI: 10.2147/COPD.S62502. View

Singh D, Ferguson G, Bolitschek J, Gronke L, Hallmann C, Bennett N . Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015; 109(10):1312-9. DOI: 10.1016/j.rmed.2015.08.002. View

Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(5 Pt 1):1418-22. DOI: 10.1164/ajrccm.157.5.9709032. View

10.

Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G . Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015; 45(4):969-79. PMC: 4391658. DOI: 10.1183/09031936.00136014. View

11.

ODonnell D, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B . Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004; 23(6):832-40. DOI: 10.1183/09031936.04.00116004. View

12.

van der Molen T, Cazzola M . Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012; 21(1):101-8. PMC: 6547888. DOI: 10.4104/pcrj.2011.00102. View

13.

Mahler D . Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006; 3(3):234-8. DOI: 10.1513/pats.200509-103SF. View

14.

Ferguson G, Feldman G, Hofbauer P, Hamilton A, Allen L, Korducki L . Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014; 9:629-45. PMC: 4064950. DOI: 10.2147/COPD.S61717. View

15.

Jones P . Estimation and application of the minimum clinically important difference in COPD. Lancet Respir Med. 2014; 2(3):167-9. DOI: 10.1016/S2213-2600(14)70038-4. View

16.

Feldman G, Bernstein J, Hamilton A, Nivens M, Korducki L, LaForce C . The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus. 2014; 3:419. PMC: 4152473. DOI: 10.1186/2193-1801-3-419. View

17.

Wu M, Zhao Q, Chen Y, Fu C, Xu B . Quality of life and its association with direct medical costs for COPD in urban China. Health Qual Life Outcomes. 2015; 13:57. PMC: 4429937. DOI: 10.1186/s12955-015-0241-5. View

18.

Perez T, Burgel P, Paillasseur J, Caillaud D, Deslee G, Chanez P . Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015; 10:1663-72. PMC: 4547644. DOI: 10.2147/COPD.S82408. View

19.

Casaburi R, Mahler D, Jones P, Wanner A, San P, ZuWallack R . A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19(2):217-24. DOI: 10.1183/09031936.02.00269802. View

20.

Donohue J, Maleki-Yazdi M, Kilbride S, Mehta R, Kalberg C, Church A . Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013; 107(10):1538-46. DOI: 10.1016/j.rmed.2013.06.001. View